TL;DR: The US Department of Health and Human Services’ Office of Research Integrity (ORI) posted three research misconduct case summaries in 2026 so far. The most significant, Ariel Fernandez, a former Rice University bioengineering professor, drew a 15-year debarment from federal contracting — effective March 25, 2026, through March 24, 2041 — after an administrative law judge upheld ORI’s finding that he fabricated and falsified data across 12 published papers, four unpublished manuscripts, a conference presentation, and three grant applications. Two other 2026 cases (Daniel Andrade at the University of Oklahoma Health Sciences Center and Chen-Yeh "George" Ke at the Icahn School of Medicine at Mount Sinai) resulted in multi-year supervision and PHS-advisory prohibitions rather than debarment. Together they show ORI’s case-adjudication pipeline continuing to move at a normal pace under the current 42 CFR Part 93 framework, which was substantively revised by a Final Rule effective January 2025.
The Fernandez case: fabrication across a body of work, not one paper
ORI’s case summary for Ariel Fernandez, PhD — former Karl F. Hasselmann Chaired Professor of Engineering in Rice University’s Department of Bioengineering — describes fabrication and/or falsification across an unusually wide span of outputs: 12 papers published with support from NIGMS/NIH grant R01 GM072614, four unpublished manuscripts, one conference presentation, and three grant applications. Per ORI’s summary, the specific conduct included fabricating the synthesis of six chemical compounds that were never actually produced, and manipulating Western blot and confocal microscopy images alongside falsified results from spectrophotometric kinetic assays, a high-throughput kinase screen, cell-proliferation assays, and ATP-production assays.
An administrative law judge, Margaret G. Brakebusch, issued a recommended decision on May 22, 2025, granting summary judgment in HHS’s favor; the Acting Assistant Secretary for Health did not call the decision up for review, which made ORI’s findings final. The resulting sanction — a 15-year debarment from covered federal transactions (March 25, 2026 through March 24, 2041), plus a 15-year prohibition from PHS advisory service running earlier, from June 22, 2025 through June 21, 2040 — is toward the long end of ORI’s typical range; most debarments run three to seven years. ORI’s notice also states it will contact the journals behind the 11 papers requiring retraction or correction. The Federal Register notice was published May 5, 2026.
The case has a long backstory that predates the 2026 finding by well over a decade. According to contemporaneous reporting by Retraction Watch, concerns about duplicated images in Fernandez’s manuscripts were first raised by a graduate student in 2009; Rice University’s own investigation found repeated falsification, the university settled with Fernandez in 2010, and he left the institution in 2011. ORI did not reopen the matter until November 2022, more than a decade later — illustrating how long a federal misconduct case can take to work through inquiry, investigation, administrative hearing, and appeal before a final case summary is published. This is an illustrative pattern point rather than a claim about the reason for that specific gap, which ORI’s summary does not itself explain.
Two other 2026 cases, different sanctions
ORI’s other 2026 case summaries show the more typical, narrower end of its sanction range:
- Daniel Andrade, PhD (University of Oklahoma Health Sciences Center, Department of Obstetrics and Gynecology and Stephenson Cancer Center) — found to have falsified and fabricated data on NIH grants DP2 OD030789-01 and R21 CA253956-01, including relabeling data from a standard cell line as if it came from cancer patient-derived organoids, splicing together Western blot images from separate experiments, and misreporting the source of a transmission electron micrograph. ORI’s notice, published February 9, 2026, imposes a three-year supervision period beginning January 11, 2026 (quarterly oversight-committee review of primary data plus advance review of research reporting) and a three-year prohibition from any PHS advisory role, including peer review.
- Chen-Yeh "George" Ke, PhD (former postdoctoral fellow, Icahn School of Medicine at Mount Sinai) — misconduct found in a draft manuscript and two NIH Research Performance Progress Reports tied to NIDCR grant R01 DE022363. ORI proposed, effective January 6, 2026, a three-year supervision period and a three-year prohibition from PHS advisory service; the respondent did not contest the findings within the 30-day notice period.
Why this matters for research administration offices
None of these three cases is evidence, on its own, of a change in ORI’s enforcement posture — three case summaries in a partial year is well within ORI’s normal historical volume, and each case originated years before 2026 (Fernandez’s underlying conduct dates to Fernandez’s Rice tenure through 2011; Andrade’s and Ke’s proposed findings were both published in late 2025/early 2026 after institutional investigations that would have started earlier). What the batch is useful for is a concrete, current reminder of what an ORI finding actually specifies once a case closes: which specific PHS grants and outputs were affected, exactly what conduct was found (image manipulation, fabricated synthesis claims, mislabeled data sources, spliced blots), what administrative sanction followed, and what obligations — retraction notices to journals, supervision plans, advisory-service bans — an institution and respondent are left managing afterward.
All three cases were adjudicated within the current version of 42 CFR Part 93, the regulation defining research misconduct and the process ORI and institutional Research Integrity Officers (RIOs) follow for PHS-supported research. That regulation was substantively revised by a Final Rule published in the Federal Register on September 17, 2024, effective in early 2025 — the version of Part 93 these 2026 findings were processed under. Research integrity offices tracking case volume or sanction patterns should read individual ORI case summaries directly rather than relying on secondary counts, since ORI does not publish a running annual tally and case summaries are posted on a rolling basis as findings become final.
Frequently asked questions
How many research misconduct cases does ORI close in a typical year?
ORI does not publish a fixed annual target, and volume varies year to year based on how many institutional investigations reach a final finding. Historically ORI has closed roughly a dozen to two dozen PHS research misconduct cases per year, with wide variation; three case summaries posted through mid-2026 is consistent with, not unusually high or low relative to, that historical range.
What sanctions can ORI actually impose?
ORI itself does not prosecute; it makes findings and the HHS Debarment Officer proposes administrative actions, which can include debarment from federal contracting/grants for a set period, supervision requirements on future PHS-supported research, prohibition from serving on PHS peer-review or advisory committees, and required correction or retraction of affected publications. Respondents can contest proposed findings before an administrative law judge, as occurred in the Fernandez case.
Where can I read the primary-source case summaries?
Directly on ORI’s own site at ori.hhs.gov/case_summary, organized by year. Each summary names the respondent, institution, funding source, specific findings, and administrative actions — these are the authoritative record, not secondary press coverage.
Sourced directly from ORI’s published case summaries (ori.hhs.gov) and, for background on the Fernandez case’s procedural history, Retraction Watch’s reporting. This is a factual summary of public federal case-summary records, not an independent editorial judgment on any respondent’s conduct.
